Treatment Details – 10.0 months

Survival: 10.0 months
  
Toxicity Grade:5
  
Treatments: Biologic therapy
Surgery
  
Drugs:
Country:Netherlands
  
City/State/Province:Amsterdam
  
Hospital:The Netherlands Cancer Institute
  
Journal:Link
  
Date: 10/2001

Description:
Patients: This Phase I/II study involved 28 patients with malignant pleural mesothelioma.

Treatment: The treatment consisted of surgery (pleuropneumonectomy) with intraoperative photodynamic therapy (the drug mTHPC). (Photodynamic therapy is a technique that uses non-thermal lasers to activate light-sensitive drugs.)

Toxicity: Three patients died in the perioperative period (the period immediately preceding, during and after a surgical procedure.) One of the three deaths was directly related to photodynamic therapy.

Results: The overall median survival time was 10 months.

Support: The study was supported in part by Scotia Pharmaceuticals, Ltd. Scotia manufactures the drug, mTHPC.

Correspondence: Paul Bass, MD, PhD

Get your free copy of
“Surviving Mesothelioma” Today!